To determine whether the more aggressive phenotype of the RASSF2 knockdown cells altered their response to chemotherapeutic agents, we treated the cells with taxol or cisplatin, two drugs commonly used in the treatment of nonsmall cell lung cancer, and measured their effects on cell death. The gene discussed is RASSF2; the disease is lung cancer.